首页> 外文期刊>Annals of General Psychiatry >Site-independent confirmation of subject selection for CNS trials: ‘dual’ review using audio-digital recordings
【24h】

Site-independent confirmation of subject selection for CNS trials: ‘dual’ review using audio-digital recordings

机译:CNS试验受试者选择的站点无关确认:使用音频数字录音进行“双重”审查

获取原文
           

摘要

Background Site-independent review of subject eligibility for central nervous system (CNS) trials has been used as a surveillance method to enhance the integrity and precision of the subject selection process. We evaluated the utility of a customized review strategy that employs site-independent review of audio-digital recordings of site-based screen interviews. Methods We applied a customized site-independent subject selection strategy in nine phase II double-blind, placebo-controlled clinical trials across the CNS spectrum. The Clinical Validation Inventory for Study Admission (C-VISATM, Boston, MA, USA) was developed as a site-independent review method that evaluates and confirms diagnoses, symptom severity, and subject validity prior to enrollment (randomization) into a clinical trial. The C-VISATM method uses audio-digital recordings of actual site-based interviews conducted at the screening visit. The recordings of these interviews accompanied by digital notes are electronically submitted for independent review and ‘dual’ scoring of key rating instruments. A multi-tiered system of site-independent reviewers either affirms subject eligibility or identifies administrative and/or clinical issues that may preclude study eligibility (screen failure). Results In this meta-analysis, 404 of 2,515 submitted C-VISATM eligibility reviews (16.1%) were challenged by tier 1 reviewers and escalated to a tier 2 reviewer. After telephone adjudication with the respective trial site investigator, 168 of these 404 tier 2 reviews (41.6%) were not approved yielding an overall screen fail rate of 6.7% for all C-VISATM submissions. The primary reasons for screen failure were insufficient documentation to support the intended diagnosis, symptom severity that did not meet protocol criteria, the presence of excluded comorbid conditions, and potential confounding factors that might obscure assessment during the trial. Conclusion The C-VISATM review process coupled with dual independent scoring of key rating instruments is a quality assurance strategy that provides a systematic site-independent eligibility filter to enhance the precision of subject selection and the integrity of study data. The C-VISATM strategy has broad applicability across the CNS spectrum because it achieves the objective of confirmatory site-independent review without producing excessive site or subject burden.
机译:背景受试者对中枢神经系统(CNS)试验资格的独立于站点的审查已被用作一种监视方法,以增强受试者选择过程的完整性和准确性。我们评估了定制审核策略的实用性,该策略采用了基于站点的屏幕采访的音频数字记录的独立于站点的审核。方法我们在中枢神经系统频谱的九个II期双盲,安慰剂对照临床试验中应用了定制的部位无关受试者选择策略。研究入场临床验证清单(C-VISA TM ,美国马萨诸塞州波士顿)是一种独立于站点的审查方法,用于在注册之前评估和确认诊断,症状严重性和受试者有效性(随机)进入临床试验。 C-VISA TM 方法使用在筛选访问中进行的基于现场的实际采访的音频记录。这些采访的记录和数字笔记会以电子方式提交,以供独立审核和关键评级工具的“双重”评分。一个由多个独立于站点的审稿人组成的多层系统可以肯定受试者的资格,也可以确定可能妨碍研究资格(筛查失败)的行政和/或临床问题。结果在本荟萃分析中,提交的2,515份C-VISA TM 资格审查中有404份(占16.1%)受到第一级审查者的质疑,并被提升为第二级审查者。在与各自的试验现场调查员进行电话裁决之后,这404条2级评论中有168条(41.6%)未被批准,所有C-VISA TM 提交的屏幕总失败率为6.7%。筛查失败的主要原因是文件不足以支持预期的诊断,症状严重程度不符合方案标准,存在排除的合并症以及可能混淆试验期间评估的潜在混杂因素。结论C-VISA TM 审查过程与关键评级工具的双重独立评分相结合是一种质量保证策略,它提供了系统的,与现场无关的资格过滤器,以提高受试者选择的准确性和研究的完整性数据。 C-VISA TM 策略在中枢神经系统频谱中具有广泛的适用性,因为它实现了独立于站点的确认性审查的目的,而不会产生过多的站点或主体负担。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号